AbCellera Biologics Inc

For the period ended Dec 31, 2023. Filed Feb 20, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Feb 20, 2024

ABCL$12.46-0.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets as of December 31, 202 and

(All figures in U.S. dollars. Amounts are expressed in thousands except share data)

	December 31, 2022	December 31, 2023
Assets
Current assets:
Cash and cash equivalents	$386,535	$133,320
Marketable securities	499,950	627,265
Total cash, cash equivalents, and marketable securities	886,485	760,585
Accounts and accrued receivable	38,593	30,590
Restricted cash	25,000	25,000
Other current assets	75,413	55,810
Total current assets	1,025,491	871,985
Long-term assets:
Property and equipment, net	217,255	287,696
Intangible assets, net	131,502	120,425
Goodwill	47,806	47,806
Investments in and loans to equity accounted investees	72,522	65,938
Other long-term assets	46,331	94,244
Total long-term assets	515,416	616,109
Total assets	$1,540,907	$1,488,094
Liabilities and shareholders' equity
Current liabilities:
Accounts payable and other liabilities	$52,497	$49,580
Contingent consideration payable	44,211	50,475
Deferred revenue	21,612	18,958
Total current liabilities	118,320	119,013
Long-term liabilities:
Operating lease liability	76,675	71,222
Deferred revenue	19,516	8,195
Deferred government contributions	40,801	95,915
Contingent consideration payable	16,054	4,913
Deferred tax liability	33,178	30,612
Other long-term liabilities	3,086	5,906
Total long-term liabilities	189,310	216,763
Total liabilities	307,630	335,776
Commitments and contingencies
Shareholders' equity:
Common shares: no par value, unlimited authorized shares at December 31, 2022 and December 31, 2023: 286,851,595 and 290,824,970 shares issued and outstanding at December 31, 2022 and December 31, 2023, respectively	734,365	753,199
Additional paid-in capital	74,118	121,052
Accumulated other comprehensive income (loss)	(1,391)	(1,720)
Accumulated earnings	426,185	279,787
Total shareholders' equity	1,233,277	1,152,318
Total liabilities and shareholders' equity	$1,540,907	$1,488,094

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.